Differences in osteoclast formation between proximal and distal tibial osteoporosis in rats with adjuvant arthritis: inhibitory effects of bisphosphonates on osteoclasts

References

• Ackerman NR, Rooks WH 2nd, Shott L, Genant H, Maloney P, West E. Effects of naproxen on connective tissue changes in the adjuvant arthritis rat. Arthritis Rheum 1979;22:1365–74.
   PubMedGoogle Scholar
• Rodan GA, Fleisch HA. Bisphosphonate mechanism of action. J Clin Invest 1996;97:2692–6.
   PubMed Web of Science ®Google Scholar
• Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL. Paget's disease of bone: early and late responses to three different modes of treatment with amino hydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res ed) 1987;295:1301–5.
   PubMedGoogle Scholar
• Body JJ. Current and future directions in medical therapy: hyper-calcemia. Cancer 2000;88:3054–8.
   PubMedGoogle Scholar
• Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;323:1209–10.
   Google Scholar
• Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, et al. Increased bone mass with pami-dronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996;39:396–402.
   PubMedGoogle Scholar
• Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turn-over and osteodastic cytokines in early rheumatoid arthritis treated with alendronate. J Ftheumatol 1999;26:2318–23.
   Google Scholar
• Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R. Ef-fect of dodronate on established adjuvant arthritis. Ftheumatol Int 1994;14:139–47.
   Google Scholar
• Barbier A, Breliere JC, Remandet B, Roncucci R. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986;45:67–74.
   PubMed Web of Science ®Google Scholar
• Flora L. Comparative antiinflammatory and bone protective ef-fects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 1979;22:340–6.
   PubMedGoogle Scholar
• Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Ftheumatol 2003;30:474–9.
   Google Scholar
• Suzuki Y, Nishikaku F, Nakatsuka M, Koga Y. Osteoclast-like cells in murine collagen induced arthritis. J Ftheumatol 1998;25:1154–60.
   Google Scholar
• Takada Y, Kusuda M, Hiura K, Sato T, Mochizuki H, Nagao Y, et al. A simple method to assessosteodast-mediated bone resorp-tion using unfractionated bone cells. Bone Mineral 1992;17:347–59.
   PubMedGoogle Scholar
• Deodhar, AA, Woolf, AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Ftheumatol 1996;35:309–22.
   PubMedGoogle Scholar
• Goldring SR, Polisson, RP. Bone disease in rheumatological disor-ders. In: Avioli L, Krane SM, editors. Metabolic bone disease. 2nd ed. San Diego: Academic Press; 1998. p. 621–35.
   Google Scholar
• Gough A, Sambrook P, Devlin, J, Huissoon A, Njeh C, Robbins S, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Ftheumatol 1998;25:1282–9.
   Google Scholar
• Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001;44:1003–12.
   PubMed Web of Science ®Google Scholar
• Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid ar-thritis. Arthritis Rheum 2000;43:2523–30.
   PubMed Web of Science ®Google Scholar
• Adami S, Fossaluzza V, Gatti D, Fracassi E, Braga V. Bisphosphonate therapy of reflex sympathetic dystrophy syn-drome. Ann Rheum Dis 1997;56:201–4.
   PubMed Web of Science ®Google Scholar
• Ahmedzai S. New approaches to pain control in patients with cancer. Eur J Cancer 1997;33:58–14.
   Web of Science ®Google Scholar
• Nishikaku F, Nakayama T, Nakatsuka M. Analgesic property of bisphosphonate, etidronate in animal models. Jpn Pharmacol Ther 1998;26:457–63.
   Google Scholar
• Hirano K. Effects of Bisphosphonate on the inflammation. Clin Calcium 2003;13:128–33.
   PubMedGoogle Scholar
• Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposo-mat and free bisphosphonate on the IL-1 beta, IL-6 and TNF-alpha secretion from RAW 264 cells in vitro. Pharm Res 1995;12:916–22.
   PubMed Web of Science ®Google Scholar
• Zhao H, Shuto T, Hirata G, Iwamoto Y. Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis. J Orthop Sci 2000;5:397–403.
   PubMedGoogle Scholar
• Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 1996;119:205–12.
   Google Scholar
• Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000;43:1951–9.
   PubMed Web of Science ®Google Scholar
• Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clini-cal, biochemical, and radiographic effects of aminohydroxypro-pylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989;48:396–9.
   Google Scholar
• Tan PLH, Ames R, Yeoman S, Ibbertson HK, Caughey DE. Ef-fects of amino bisphosphonates infusion on biochemical indices of bone metabolism in rheumatoid arthritis. Br J Pharmacol 1989; 28:325–8.
   Google Scholar
• Dunn CJ, Galinet LA, Wu H, Nugent RA, Schlachter ST, Staite ND, et al. Demonstration of novel anti-arthritic and anti-inflammatory effects on diphosphonates. J Pharmacol Exp Ther 1993;266:1691–8.
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Doyle DV, Willoughby DA. Investigation of the acute and chronic anti-inflammatory properties of diphosphonates using a broad spectrum of immune and non-immune inflammatory reac-tion. Drug Dev Res 1993; 28:47–55.
   Google Scholar
• Yamamoto K, Yoshino S, Shue G, Nagashima M. Inhibitory effect of bone resorption and inflammation with intermittent cyclical etidronate therapy in rheumatoid arthritis for three years and in vitro study. Ftheumatol Int online first 2006;27:627–32.
   Google Scholar